communityacquir
pneumonia
cap
common
infecti
diseas
encount
commun
world
frequent
affect
young
elderli
associ
signific
mortal
morbid
sever
case
pneumonia
third
frequent
caus
death
worldwid
howev
statist
global
region
incid
econom
burden
cap
lack
estim
million
case
cap
occur
year
usa
approxim
requir
hospit
usa
cap
age
account
million
physician
visit
annual
million
hospit
year
estim
cost
billion
annual
holland
estim
incid
cap
averag
per
popul
per
year
cost
european
union
million
year
total
popul
million
howev
analysi
includ
direct
cost
hospit
indirect
econom
burden
loss
employ
limit
data
avail
incid
econom
burden
cap
workingag
popul
age
year
studi
usa
overal
incid
rate
cap
lowrisk
group
per
person
year
requir
hospit
averag
annual
increment
cost
rang
inpati
manag
patient
cap
outpati
manag
nasopharynx
normal
respiratori
tract
provid
complex
seri
mechan
protect
lower
respiratori
tract
noxiou
agent
microbi
pathogen
initi
includ
aerodynam
barrier
nasopharynx
cough
reflex
mucociliari
clearanc
foreign
materi
invad
tracheobronchi
tree
local
product
immunoglobulin
iga
igg
ige
mucosa
respiratori
tract
provid
anoth
layer
protect
invad
microb
rel
proport
iga
igg
respiratori
tract
chang
locat
greater
ratio
iga
igg
nasal
mucosa
trachea
bronchial
tree
revers
ratio
alveoli
greater
proport
igg
iga
may
import
protect
viral
infect
neutral
sever
respiratori
virus
rhinoviru
influenza
respiratori
syncyti
viru
may
involv
mechan
preferenti
bacteri
adher
wherea
individu
iga
defici
increas
respiratori
infect
igg
certain
igg
subclass
defici
recurr
respiratori
infect
igg
limit
invas
microorgan
epithelium
opson
complement
fixat
concentr
increas
hundredfold
respiratori
tract
presenc
infect
increas
vascular
permeabl
protect
respiratori
tract
microbi
invad
complex
process
involv
mani
immun
cell
dendrit
cell
b
tlymphocyt
neutrophil
macrophag
secretori
product
immunoglobulin
cytokin
opsonin
enzym
oxygen
metabolit
nonimmun
opsonin
surfact
fibronectin
fragment
possibl
creactiv
protein
recent
studi
indic
progranulin
autocrin
growth
factor
express
varieti
tissu
cell
type
play
protect
role
lung
immun
bacteri
pneumonia
elev
progranulin
level
observ
clinic
experiment
bacteri
pneumonia
mediat
host
defens
gramposit
gramneg
bacteri
pneumonia
healthi
mucosa
colon
complex
milieu
microorgan
exclus
aerob
anaerob
bacteria
probabl
play
import
protect
role
invad
pathogen
normal
microb
prevent
establish
invad
pathogen
microb
respiratori
epithelium
first
step
induc
infect
past
decad
mark
interest
research
role
normal
microbiom
respiratori
tract
health
diseas
facilit
modern
sophist
molecular
multiom
techniqu
recent
studi
human
microbiom
includ
respiratori
tract
demonstr
resid
microflora
much
abund
divers
previous
realiz
includ
mani
speci
noncultur
bacteria
virus
virom
fungi
protozoa
present
data
indic
microbiom
gut
lung
link
immun
cell
mediat
mayb
import
associ
pathogenesi
respiratori
diseas
bronchial
tract
harbor
complex
dynam
microbi
milieu
speci
overlap
oral
microbiom
lung
also
colon
airway
microbiota
resembl
microbiom
mouth
nostril
lower
densiti
studi
link
dysbiosi
respiratori
microbiom
asthma
chronic
lung
diseas
cystic
fibrosi
bronchiectasi
chronic
obstruct
pulmonari
diseas
copd
howev
data
yet
associ
acut
pneumonia
gener
believ
cap
occur
aspir
pathogen
microb
colon
nasopharynx
situat
defect
normal
airway
defens
incit
factor
may
play
role
develop
pneumonia
includ
preced
viral
upper
respiratori
tract
infect
seen
nearli
bacteri
cap
minor
infect
result
defect
mucociliari
function
clearanc
aspir
bacteria
allow
adher
pathogen
mucosa
quit
possibl
upper
respiratori
viru
infect
result
dysbiosi
commens
respiratori
microbiom
cigarett
smoke
similar
effect
airway
defens
associ
dysbiosi
resid
microbiota
interpret
studi
util
comprehens
molecular
method
etiolog
diagnosi
cap
find
virus
pathogen
bacteria
nasopharyng
sputum
specimen
may
prove
causal
pneumonia
clearli
caus
upper
tract
infect
colon
without
produc
lower
respiratori
diseas
howev
absenc
specif
pathogen
these
assay
effect
exclud
etiolog
agent
sinc
nearli
cap
result
aspir
upper
airway
microb
combin
test
sputum
gram
stain
cultur
blood
cultur
urinari
antigen
antibodi
respons
microb
may
specif
reliabl
method
determin
causal
highli
sensit
provid
rapid
result
affect
manag
futur
research
focu
rapid
readili
avail
inexpens
test
etiolog
diagnosi
cap
could
use
emerg
depart
method
may
use
immunoassay
could
detect
variou
bacteri
pathogen
antigen
semiquantit
sputum
blood
urin
form
dipstick
similar
urinalysi
test
case
cap
diagnosi
straightforward
sinc
advent
chest
radiograph
signific
advanc
diagnost
method
typic
mild
case
cap
clinic
symptom
recent
cough
fever
presenc
chest
crackl
may
treat
empir
without
chest
xray
blood
test
howev
normal
chest
examin
present
cap
chest
radiograph
standard
investig
confirm
pneumonia
suspect
case
done
cap
even
presenc
typic
chest
find
defin
extent
lung
involv
assess
presenc
parapneumon
effus
possibl
empyema
presenc
pulmonari
cavit
abscess
presenc
necrot
pneumonia
restrict
etiolog
diagnosi
bacteria
usual
requir
longer
durat
therapi
diagnosi
cap
difficult
complic
case
often
sever
case
multiorgan
failur
dysfunct
requir
intens
care
situat
difficulti
lie
interpret
chest
xray
problem
aris
differenti
pneumonia
pulmonari
edema
hemorrhag
atelectasi
acut
respiratori
distress
syndrom
ard
computer
tomographi
ct
scan
may
may
abl
differenti
condit
bedsid
ultrasonographi
use
diagnos
pneumonia
less
reliabl
radiographi
sensit
rang
specif
ultrasound
use
defin
presenc
sever
associ
pleural
effus
investig
also
assess
valu
molecular
biomark
sever
ill
patient
differenti
cap
noninfecti
caus
lung
infiltr
studi
patient
admit
intens
care
unit
icu
suspect
cap
genomewid
transcript
profil
blood
leucocyt
investig
express
proinflammatori
antiinflammatori
pathway
similar
patient
without
cap
blood
concentr
biomark
procalcitonin
interleukin
il
interleukin
discriminatori
analysi
reveal
ratio
two
gene
best
distinguish
cap
nocap
ratio
provid
posit
predict
valu
neg
predict
valu
howev
clinic
util
manag
serious
ill
patient
question
studi
need
standard
predict
score
appli
patient
seen
hospit
ed
cap
main
contenti
issu
whether
patient
score
admit
treat
outpati
may
reason
admit
patient
one
factor
age
year
alon
use
age
alon
admiss
support
evid
almost
everi
medic
ill
howev
patient
year
older
signific
comorbid
ill
underli
cardiovascular
diseas
admit
monitor
patient
admit
hospit
idsaat
guidelin
mayb
appropri
use
decid
care
icu
although
scap
smartcop
score
suitabl
well
current
data
indic
amoxicillin
outpati
treatment
cap
day
prefer
therapi
macrolid
monotherapi
avoid
due
high
rise
resist
pneumonia
furthermor
moder
macrolid
resist
pneumonia
report
analysi
resist
mutat
gene
amoxicillinclavulan
acid
mayb
prefer
cover
strain
h
influenza
catarrhali
elderli
subject
copd
chronic
bronchiti
patient
admit
hospit
cap
requir
icu
care
treat
monotherapi
commonli
ceftriaxon
amoxicillinclavulan
acid
use
respiratori
quinolon
oral
whenev
pneumococcu
shown
etiolog
agent
penicillin
use
evid
outcom
advers
affect
penicillin
nonsuscept
rel
resist
strain
cap
even
bacteremia
patient
sever
cap
requir
icu
care
ceftriaxon
macrolid
quinolon
alon
suitabl
set
macrolid
use
l
pneumophila
infect
organ
exclud
cap
adjunct
macrolid
benefici
random
studi
still
need
sever
case
risk
icu
manag
steroid
may
benefici
reduc
mortal
ard
mechan
ventil
sever
cap
result
conclus
thu
would
prematur
use
steroid
routin
sever
cap
pend
larger
rct
subgroup
patient
admit
hospit
recent
review
metaanalysi
steroid
hospit
patient
cap
analysi
case
six
trial
steroid
reduc
time
clinic
stabil
length
hospit
stay
day
reduc
mortal
increas
risk
hyperglycemia
caprel
rehospit
state
art
reminisc
data
steroid
sepsissept
shock
steroid
appear
effect
reduc
mortal
base
small
rct
proven
ineffect
larger
definit
trial
least
three
larg
trial
regist
clinic
trialsgov
expect
enrol
total
patient
schedul
complet
octob
provid
definit
data
use
steroid
cap
futur
trial
investig
effect
ad
nonsteroid
antiinflammatori
agent
nsaid
treatment
cap
recent
open
random
trial
hong
kong
patient
hospit
sever
influenza
pulmonari
infiltr
significantli
lower
mortal
shorter
hospit
stay
treatment
day
oseltamivir
oseltamivir
group
receiv
betalactam
antibiot
effect
treatment
clearli
need
smoke
cessat
worldwid
prevent
lung
cancer
cardiovascular
diseas
copd
mani
associ
cancer
ill
includ
possibl
cap
although
univers
annual
influenza
vaccin
recommend
children
adult
rate
vaccin
countri
low
popul
improv
effect
long
last
influenza
vaccin
given
nasal
oral
rout
need
facilit
greater
complianc
herd
immun
meantim
physician
encourag
annual
influenza
vaccin
offer
elderli
highrisk
adult
cap
pend
develop
market
conjug
pneumococc
vaccin
reason
administ
well
sever
month
later
